Abstract
Markers of cognitive impairment in patients with type 2 diabetes
Data indicate that patients with type 2 diabetes (T2D) are at increased risk of developing cognitive dysfunction/ dementia, yet the pathophysiological mechanisms that underlie and correlate these two conditions have not been completely elucidated (1) . The literature suggests several risk factors possibly associated with or contributing to the diabetes-related cognitive impairment/ dementia, such as chronic hyperglycemia with accumulation of advanced glycation end products, repetitive hypoglycemic episodes, hyperinsulinemia and insulin resistance (with associated impairment in insulin signaling in the brain), impaired amyloid clearance with abnormal cerebral amyloid deposition, dyslipidemia, oxidative stress, inflammation, hormonal factors or vascular dysfunction (2) . Cognitive impairment results in negative health outcomes including poor diabetes management and decreased life expectancy (3) . The aim of this study was to evaluate the correlations between cognitive function, as evaluated by the Montreal Cognitive Assessment test (MoCA), and a panel of metabolic, nutritional, hormonal, and immunologic parameters in subjects with T2D, in an attempt to identify biomarkers of cognitive impairment in this patient population. Of a larger number of parameters of potential interest for our purpose, we chose those that are diabetes-specific (e.g. C-peptide, fasting blood glucose, HbA1c), clinically relevant for patients with T2D (e.g. lipids, adiponectin, leptin, TSH, cortisol) or potentially significant in terms of pathophysiological mechanisms (e.g. nutrients, inflammatory markers).
Material and methods
This was a cross-sectional study that included patients with T2D regularly seen in the Diabetes, Nutrition and Metabolic Diseases Outpatient Unit of the Emergency County Clinical Hospital in Tîrgu Mureş and age-and gender-matched healthy control (HC) subjects. This evaluation was part of a larger study that included assessment of depression and anxiety, with an additional depression group, but this data are not presented here. We present only the data related to cognitive function. The study was approved by the Ethics Committee of the Emergency County Clinical Hospital of Tîrgu Mureş and that of the University of Medicine and Pharmacy of Tîrgu Mureș, and the patients signed an informed consent before participating in the study.
The subjects were included in the study if they were ≥ 30 years old, either had a previous diagnosis of T2D or were healthy (defined by this protocol as without depression/ T2D), had at least minimal literacy (able to read and write) and were fluent in Romanian language. Exclusion criteria were type 1, secondary or gestational diabetes (for T2D group), diabetes or depression (for HC group), severe diseases (such as, but not exclusively: severe autoimmune diseases or cancer diagnosed less than 5 years before) for all. Diagnosis of diabetes was set according to the American Diabetes Association (ADA) criteria (4).
The cognitive status was evaluated by the Romanian version of the MoCA test. The permission to use the questionnaire was kindly obtained from Kathleen Gallant, MSOT, on behalf of Dr Ziad Nasreddine, MoCA© Copyright Owner. The MoCA is a cognitive screening test rated on a 30-point scale that also adjusts for the level of education, as for ≤ 12 grades of formal education 1 point is added. A score ≥ 26 points is considered normal, 17-25 points denote mild cognitive impairment, 10-16 points moderate cognitive impairment, while < 10 points severe cognitive impairment, respectively (5) .
The following details were collected from all the participants: demographic (age, gender, ethnicity, residence, socio-economic status, level of education), clinical data (personal and family history, current therapy, blood pressure, heart rate, smoking, alcohol use), and anthropometric measurements (weight, height, waist and hip circumference) obtained. The body mass index (BMI) and waist-to-hip ratio were calculated.
Of 145 patients with T2D and 23 HC subjects fasting blood samples were obtained within two weeks from inclusion in the study. Samples were collected by venipuncture in the morning, between 8.00-9.00 am, after an overnight fast and then immediately centrifuged. Serum was aliquoted and stored at -80°C for subsequent tests. Glycated hemoglobin (HbA1c) samples were stored at 4°-8ºC and analyzed within one week.
C-peptide, vitamin B12, and high-sensitivity C-reactive protein (hsCRP) concentrations were measured by chemiluminescent immunometric assay, according to the manufacturer's instructions (Immulite ® 1000; Immulite Siemens kits). As stated by the manufacturer, the functional sensitivity of the method for C-peptide was 0.09 ng/ml and total coefficient of variation (CV) was 5.5%. For vitamin B12, the total CV for intra-assay precision were 11.3% and analytical sensitivity was 125 pg/ml. The functional sensitivity of the method for hsCRP was 0.3 mg/l and total CV was 10.0%.
Leptin and adiponectin were measured by the enzyme-linked immunosorbent assay (ELI-SA) method (ELISA MiniBos, Biomedica), according to the manufacturers' instructions. The analytical sensitivity for the leptin kit was 1.0 ng/ml and the CV for the intra-assay variability were 6.91% (DRG Instruments, Germany). For the adiponectin kit, the analytical sensitivity was 0.338 ng/ml, while the CV for the intra-assay variability were 3.4% (Immundiagnostik AG, Bensheim).
HbA1c, lipid parameters (low density lipoprotein (LDL)-cholesterol, high density lipoprotein (HDL)-cholesterol, triglycerides), cortisol, thyroid-stimulating hormone (TSH) and magnesium (Mg) concentrations were determined by the use of a Cobas 6000 analyzer (c501 and e601 modules) (Roche Diagnostics). Total cholesterol was calculated by the Friedewald formula, except when triglyceride values were > 400 mg/dl, in which cases total cholesterol was measured by the same method/ analyzer. The functional sensi-tivity for the cortisol kit was < 8.5 nmol/l, while for TSH it was 0.014 μIU/ml, as stated by the manufacturer. Blood glucose was measured by the glucose-oxidase method and a mean of the two measurements was calculated.
By using the Homeostasis Assessment Model (HOMA) calculator version 2.2.3, based on fasting glucose and C-peptide concentrations, we estimated the insulin resistance (HOMA IR) and beta cell function (HOMA B%) (6) .
Descriptive statistics were performed for all variables and expressed as mean ± SD or median (min-max) for normal or non-normally distributed continuous variables, respectively, and frequency (%) for categorical variables. Normality of data was checked by Kolomogrov-Smirnov test. Student t test, Mann-Whitney test, ANO-VA and Kruskal-Wallis tests were employed to compare means and medians between groups. Fisher's exact test was used for analysis of categorical variables, and the odds ratios (OR) with 95% confidence interval (CI) were calculated for categorical comparisons. We also used Dunn or Bonferroni multiple comparison post-test to identify the groups between which there were significant differences. Spearman's correlation coefficients were calculated to evaluate the relationship between the variables of interest. Multiple regression analysis was used to evaluate the correlations between more than two variables. All tests were two-tailed and the statistical significance was set at p < 0.05. Statistical analysis was performed by using GraphPad InStat3.
Results
The study finally included and analyzed data for 216 patients with T2D and 23 HC individuals who agreed to participate (excluded: 1 patient with secondary diabetes and 5 subjects from the HC group -2 had depression scores at least at one questionnaire, 3 had blood glucose values of diabetes). These groups were matched for age (62.2 ± 7.8 years in the T2D group vs. 61.6 ± 7.0 years in the HC group, p > 0.05) and gender (Female/ Male: 61.5%/ 38.4% in the T2D vs. 60.9%/ 39.1% in the HC group, p > 0.05). No significant differences were noted for demographic parameters between the two groups, except for ethnicity: the percentages of Romanians/ Hungarians/ Rroma/ Germans were 74.5%/ 23.6%/ 1.9%/ 0.0% in the T2D group, and 78.0%/ 17.4%/ 0.0%/ 4.3% in the HC group (p: 0.01).
As we showed in a previous report, administration of the MoCA test in patients with T2D conveyed the following results: 54/ 216 (25.0%) had normal cognitive function scores, 149/ 216 (69.0%) had mild, 13/ 216 (6.0%) had moderate, and none had severe cognitive dysfunction scores (7) . In contrast, in the matched HC group, 11/ 23 (47.8%) had mild cognitive impairment and 12/ 23 (52.2%) had normal cognitive function scores (≥ 26 points), while none had moderate or severe cognitive impairment scores (p: 0.04). Moreover, there was a significant difference in the median MoCA scores between the two groups (26.0 (17.0-29.0) points in HC vs. 23.0 (13.0-31.0) points in T2D group; p: 0.004).
We then divided the T2D group according to the cognitive function scores. The demographic and clinical data is presented in Table 1 . Even if there was no difference in duration of diabetes between the three groups, patients with cognitive dysfunction were significantly older (p < 0.0001) ( Table 1) . There was also a significant negative correlation of age with MoCA scores (-0.31; 95%CI: -0.42, -0.18; p < 0.0001). Male patients with T2D and normal cognitive function scores had higher waist scores compared to the other two DZ groups ( There was a significant difference between the three cognitive function groups with regards to the level of education (p < 0.0001) ( Table 1) . Moreover, when T2D patients were stratified according to the level of education, there was a significant difference between MoCA scores (< 8 grades: 18.3 ± 2.6 points, < 12 grades: 21.2 ± 3.5 points, high school: 23.8 ± 3.4 points, post-secondary school: 23.0 ± 2.9 points, university: 24.6 ± 2.6 points, post-graduate education: 26.0 ± 2.6 points; p < 0.0001). For the purpose of comparing the MoCA scores in patients with T2D and HC, data were grouped in three levels of education (< 12 grades; high school & post-secondary school; university & post-graduate education), because the number of subjects in the HC group was relatively small. The difference in MoCA scores was significant only in patients with T2D, but not in HC (Figure 1) . In addition, patients with T2D and high-school & post-secondary school education had significantly lower scores compared to HC subjects with the same level of education (24. When the results were analyzed according to the cognitive function, patients with T2D with mild and moderate cognitive impairment presented dysfunctions in all but the orientation domain (p < 0.0001 for all) (Figure 2b) , while HC group with mild cognitive impairment had lower scores in language and delayed recall domains compared with HC with normal cognitive function (45.5% (1.4 out of 3 points) vs. 77.8% (2.3 out of 3 points), p: 0.02 and 43.6% (2.2 out of 5 points) vs. 73.3% (3.7 out of 5 points), p: 0.005, respectively) (Figure 2) .
All HC subjects and 145 T2D patients had laboratory tests evaluation. The results are presented in Table 2 . One cortisol value was excluded (outlier). Subjects with T2D had higher HbA1c, fasting blood glucose, triglyceride and fasting C-peptide levels, while HC subjects had higher total cholesterol, LDL-and HDL-cholesterol values ( Table 2) . In addition, patients with T2D had higher scores of insulin resistance (HOMA IR), while no significant difference was seen in beta cell function (HOMA B%) ( Table 2) . Mean serum Mg levels were significantly different in the 5 groups (p < 0.0001; Table 2 ). The difference was statistically significant between the moderate cognitive impairment T2D group and both HC groups (p < 0.05 and p < 0.01) and between the mild cognitive impairment T2D group and both HC groups (p < 0.01 and p < 0.001).
When serum Mg levels were compared only between T2D groups, there was a significant difference (p < 0.01), with both cognitive impairment groups having significantly lower Mg concentration vs. normal cognitive group (p < 0.05 for both). No other significant difference was noted for laboratory parameters between the three T2D groups (p: NS for all). Overall, patients with T2D had significantly lower serum Mg concentrations compared to matched-HC ( Table 2) .
We further analyzed the correlation of MoCA scores with various metabolic, nutritional, hormonal, and immunologic laboratory parameters ( Table 3 ). In subjects with T2D, the MoCA scores were positively correlated with serum Mg levels (0.24, 95%CI: 0.07; 0.39; p: 0.003) (Figure 3) . No significant correlations were found between MoCA score and cognitive domains, respectively with HOMA IR and HOMA B% (data not shown). After adjustment for HbA1c, LDL-cholesterol, HDL-cholesterol, triglyceride, TSH, cortisol, hsCRP, C-peptide, vitamin B12, leptin, adiponectin values in a multiple linear re- Finally, we analyzed the correlation of each laboratory parameter with each cognitive domain assessed by the MoCA test (Table 3 ). In patients with T2D total cholesterol and HDL-cholesterol significantly correlated with delayed recall scores (p: 0.01 and p: 0.02, respectively; Table 3 ). Serum Mg levels correlated with visuospatial/ executive and naming scores (p: 0.0002 and p: 0.02, respectively; Table 3 ). In addition, a negative correlation of serum leptin levels and the scores of visuospatial/ executive and language domains was noted (p: 0.02 and p: 0.007, respectively; Table 3 ).
Discussions
Firstly, our study confirms that patients with T2D have significantly lower cognitive function scores compared with healthy individuals (along with high prevalence of cognitive impairment, as previously shown) (7) . This indicates that the neurocognitive complications are important conditions that require attention in patients with T2D. The causes of the T2D-related cognitive impairment have not yet been fully clarified. Some research suggests that the neurodegenerative, cerebrovascular processes and associated brain atrophy might be the link to cognitive dysfunction (8, 9) . Most probably, T2D is associated with a mixed pathology in the brain and no single specific vascular or metabolic risk factor has been identified as a determinant of accelerated cognitive decline, which is reported to be rather multifactorial (10, 11) .
In our study, younger age and higher education significantly correlated with better cognitive function in patients with T2D, even if the MoCA test was already adjusted for the level of education. These results are consistent with those reported in other studies performed in subjects with T2D (12, 13) .
In addition to having lower MoCA test scores, subjects with T2D performed worse in the visuospatial/ executive and delayed recall cognitive domains compared with healthy individuals. Other studies have indicated significant decline in several cognitive domains such as memory, executive function, language, processing speed and attention in patients with T2D, but findings were not uniform (14) (15) (16) . This could be due to differences in the population group, cognitive evaluation, study design, or data analysis between studies. A recent study in Japanese patients with T2D that also employed the MoCA test to evaluate cognitive function/ domains has shown that patients with diabetes and mild cognitive impairment had lower scores for frontal lobe function (attention, language and abstraction) and delayed recall (17) . Moreover, a recent systematic review and meta-analysis of 15 studies (n=23796; 2370 with T2D) has confirmed that T2D is associated with impairment in memory and executive function (18) . A longitudinal study with a 12-year follow-up reported that individuals with T2D presented accelerated cognitive decline, mainly in the information-processing speed, executive function and delayed word recall compared with subjects without diabetes (19) . Interestingly, another longitudinal study that evaluated the impact of transition in glucose status over 2 years, has demonstrated that individuals who presented incident glucose disorders had greater decline in global cognition and visuospatial function as well as in total brain volume, compared with normal (20) . Apparently, various brain areas are involved in the visuospatial/ executive and delayed recall functions as assessed in the MoCA test (fronto-parieto-occipital cortices for the visuospatial/ executive function and hippocampal-parieto-frontal areas for retrieval memory, respectively) (21) . Neuroimaging studies have shown that patients with T2D have global brain atrophy, but also regional atrophy in the hippocampus and prefrontal regions, which may explain at least in part the cognitive deficits seen in these patients (9, 13) . In fact, there is some evidence that higher blood glucose levels, even in the normal range, are associated with atrophy in the hippocampus and amygdala, brain regions critically important for memory (22) . Functional imaging data further suggests diminished connectivity between the hippocampus and the frontal and temporal regions (23) . Thus, atrophy in the hippocampal area and altered neuronal connectivity might be responsible for the memory impairment in subjects with T2D (23).
We observed gender differences in cognitive domains evaluated by the MoCA test: female patients with T2D performed worse in the visuospatial/ executive, naming and language domains compared with men, but better in delayed recall function. The literature seems to suggest that there are gender differences in specific cognitive ability domains, that start early in life, as well as in the rate of cognitive decline, but this has been little studied in patients with T2D (24) . An Israeli study noted similar findings in T2D patient: women outperformed men in memory functions, while men outperformed women in praxis (executive) and shape (attention) functions (12) .
When we evaluated the correlations between the cognitive function and metabolic, nutritional, hormonal, and immunologic parameters in subjects with T2D, we only found positive association between serum Mg levels and cognitive function, which remained significant after adjustment for other parameters. Literature regarding the role of Mg in cognitive function of patients with T2D is relatively scarce. A few studies found correlations between low serum Mg levels and cognitive impairment in other diseases, including Alzheimer's disease (AD) (25, 26) . Some data seem also to indicate low brain Mg levels in patients with AD, although other studies have found no correlation between Mg and AD (27, 28) . A more recent longitudinal study in cognitively healthy individuals followed-up for 8 years showed that higher dietary Mg intake was associated with lower risk of mild cognitive impairment (29) . The mechanisms by which Mg might protect from cognitive impairment are not entirely clear. Some in vitro and animal studies have shown that Mg is associated with reduced production and increased degradation of toxic hyperphosphorylated protein tau, modulation of amyloid-beta protein precursor processing, reduction of neuro-inflammation and protection of synaptic plasticity (30) (31) (32) (33) . T2D often seems to be accompanied by alteration of Mg status, with reduction of serum and intracellular free Mg levels, which is associated with decreased insulin sensitivity (34). This might be one possible explanation for the observation that patients with T2D are at increased risk of cognitive impairment. We also noted lower serum Mg levels in T2D patients compared with healthy controls.
In addition, there were significant correlations between lower Mg levels and impairment of the visuospatial/ executive and naming domains in these patients. A recent study in older subjects with cognitive impairment showed that a compound containing a Mg salt improved the overall cognitive ability, the executive function and memory, but these results need further confirmation (35) . Although lipid concentrations did not correlate with overall cognitive function, total and LDL-cholesterol levels were associated with delayed recall domain. The role of lipids in the development of cognitive dysfunction in patients with T2D remains unclear, as the results of observational and interventional studies are not uniform (2) . A study in old non-demented adults showed that non-carriers of the ApoE4 allele with highest total and LDL-cholesterol had best memory scores, while another recent study indicated that LDL-cholesterol levels positively associated with memory (36, 37) . A study in the LDL-receptor knock-out mice showed impaired spatial memory and increased synaptic deficits and apoptosis in the hippocampus (38) . Cholesterol homeostasis and metabolism in the brain is complex and requires further investigations. Finally, our results indicate a negative correlation between leptin and visuospatial/ executive and language functions. A study in older adults also showed a negative association between serum leptin levels and executive function, while the Edinburgh Type 2 Diabetes Study reported that higher leptin concentrations were associated with overall cognitive decline and poorer executive function performance only in men with T2D (39, 40) . Further research is needed in order to elucidate the implications of leptin in various cognitive functions in subjects with diabetes.
Our study has certain limitations, but it also identifies areas for future research. Firstly, this was a single-center study with a relatively low number of healthy subjects that did not allow a full comparison with patients with T2D. Because of its cross-sectional design, the changes of the cognitive function/ domains in time, as well as the temporal relationship with laboratory parameters could not be evaluated. It would be interesting to assess these parameters in newly diagnosed T2D patients and monitor their change in time, along with the progressive deterioration of cognitive function/ domains. Another drawback is that we could not simultaneously study through imaging techniques the brain levels of various parameters (e.g. Mg) and correlate them with the cognitive and laboratory results, but this could also be addressed by future research that could help elucidate the underlying mechanisms of T2D-related cognitive impairment. Finally, the monitoring of the efficacy of therapeutic interventions (e.g. Mg supplementation) on cognitive function or prevention of cognitive deterioration in patients with T2D could be performed in future research.
Conclusions
Patients with T2D presented significant cognitive impairment, with decrements in the visu-ospatial/ executive and delayed recall cognitive domains. Female patients performed better than men in delayed recall function but worse in the visuospatial/ executive, naming and language domains. Younger age and higher education correlated with better cognitive function. Serum Mg levels were significantly lower in patients with T2D and correlated positively with the overall cognitive function, as well as with visuospatial/ executive and naming domains.
